Budget impact analysis of a digital monitoring platform for COPD

Table 5 Per-member per-month 3-year budget impact results from scenario analyses

Costs, USD	Base case	Scenario 1A	Scenario 1B	Scenario 2A	Scenario 2B
Commercial perspective
Budget impact	− 1.60	0.49	0.14	0.50	− 0.55
Propeller	0.13	0.13	0.13	0.13	0.13
Hospitalizations	− 1.37	− 0.33	− 0.33	− 1.00	− 1.00
ED visits	− 0.16	− 0.01	− 0.01	− 0.03	− 0.03
Outpatient/physician office	0.00	0.00	0.00	0.00	0.00
Remote monitoring	0.42	0.42	0.42	0.42	0.42
SABA use	− 0.11	− 0.11	− 0.11	− 0.11	− 0.11
Controller medication use	0.00	0.35	Not included	1.04	Not included
Medicare perspective
Budget impact	− 1.70	1.88	0.88	2.83	− 0.15
Propeller	0.37	0.37	0.37	0.37	0.37
Hospitalizations	− 2.92	− 0.51	− 0.51	–1.52	− 1.52
ED Visits	− 0.18	− 0.01	− 0.01	− 0.03	− 0.03
Outpatient/physician office	0.00	0.00	0.00	0.00	0.00
Remote monitoring	1.21	1.21	1.21	1.21	1.21
SABA use	− 0.32	− 0.32	− 0.32	− 0.32	− 0.32
Controller medication use	0.00	0.99	Not included	2.98	Not included

ED: emergency department; PMPM: per-member per-month; SABA: short-acting beta-agonist
Alternative Scenario 1: PDC for controller medications increased by 0.10 and reductions in inpatient care (5.20%) and ED visits (1.15%) where changes in controller medication costs due to changes in refill persistence either included (1A) or excluded (1B)
Alternative Scenario 2: PDC for controller medications was increased by 0.30 and reductions in inpatient care (15.60%) and ED visits (3.45%) where changes in controller medication costs due to changes in refill persistence either included (2A) or excluded (2B)

ISSN: 1478-7547